These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 11120709)
1. High antifibrinolytic activity of lipoprotein(a) containing small apolipoprotein(a) isoforms. Anglés-Cano E Circulation; 2000 Dec; 102(25):E184-5. PubMed ID: 11120709 [No Abstract] [Full Text] [Related]
2. Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis? Marcovina SM; Koschinsky ML Circulation; 1999 Sep; 100(11):1151-3. PubMed ID: 10484533 [No Abstract] [Full Text] [Related]
3. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Kronenberg F; Kronenberg MF; Kiechl S; Trenkwalder E; Santer P; Oberhollenzer F; Egger G; Utermann G; Willeit J Circulation; 1999 Sep; 100(11):1154-60. PubMed ID: 10484534 [TBL] [Abstract][Full Text] [Related]
4. [Lipoprotein(a): importance for the fibrinolytic system and thromboembolic complications]. Leischik R; Dworrak B Herz; 2006 Apr; 31(2):144-52. PubMed ID: 16738838 [TBL] [Abstract][Full Text] [Related]
11. Identification of mutations in human apolipoprotein(a) kringle 4-37 from the study of the DNA of peripheral blood lymphocytes: relevance to the role of lipoprotein(a) in atherothrombosis. Scanu AM Am J Cardiol; 1995 Feb; 75(6):58B-61B. PubMed ID: 7863976 [TBL] [Abstract][Full Text] [Related]
14. Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Horejsí B; Ceska R Physiol Res; 2000; 49 Suppl 1():S63-9. PubMed ID: 10984073 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Sechi LA; Zingaro L; Catena C; Perin A; De Marchi S; Bartoli E Kidney Int; 1999 Sep; 56(3):1049-57. PubMed ID: 10469373 [TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein a polymorphism predicts lipoprotein a concentration in renal transplant recipients. Argani H; Ghorbanihaghjo A; Rashtchizadeh N; Rahbaninobar M Transplant Proc; 2005 Sep; 37(7):2925-8. PubMed ID: 16213263 [TBL] [Abstract][Full Text] [Related]
17. Structural basis for the presumptive atherothrombogenic action of lipoprotein(a). Facts and speculations. Scanu AM Biochem Pharmacol; 1993 Nov; 46(10):1675-80. PubMed ID: 8250952 [No Abstract] [Full Text] [Related]
18. Lipoprotein[a]: a predictor of atherosclerotic disease. Harris ED Nutr Rev; 1997 Mar; 55(3):61-4. PubMed ID: 9170891 [TBL] [Abstract][Full Text] [Related]
19. Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma. Nardulli M; Durlach V; Pepe G; Anglés-Cano E Thromb Haemost; 2005 Jul; 94(1):75-81. PubMed ID: 16113787 [TBL] [Abstract][Full Text] [Related]
20. ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Kimak E; Solski J Ren Fail; 2002 Jul; 24(4):485-92. PubMed ID: 12212828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]